(Q35012986)

5 August 2017

1 reference

title

Thalidomide-associated deep vein thrombosis and pulmonary embolism (English)

1 reference

5 August 2017

0 references

1 reference

1 reference

Charles L Bennett

1

1 reference

5 August 2017

Glen T Schumock

2

1 reference

5 August 2017

Apurva A Desai

3

1 reference

5 August 2017

Hau C Kwaan

4

1 reference

5 August 2017

Dennis W Raisch

5

1 reference

5 August 2017

Rebecca Newlin

6

1 reference

5 August 2017

Walter Stadler

7

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

American Journal of Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

113

1 reference

5 August 2017

issue

7

1 reference

5 August 2017

page(s)

603-606

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

THALIDOMIDE AND CONGENITAL ABNORMALITIES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Thalidomide and venous thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Deep venous thrombosis and thalidomide therapy for multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Thromboembolic events during treatment with thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

The thrombophilic state induced by therapeutic agents in the cancer patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Multiple Myeloma. Advances in disease biology: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Thrombogenic role of cells undergoing apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Oxidant stress and endothelial cell dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Interferon-gamma modulates the fibrinolytic response in cultured human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901300-1

10.1016/S0002-9343(02)01300-1

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference